505 filings
ARS
2023 FY
ALNY
Alnylam Pharmaceuticals Inc
1 Apr 24
Annual report to shareholders
4:37pm
DEFA14A
ALNY
Alnylam Pharmaceuticals Inc
1 Apr 24
Additional proxy soliciting materials
4:34pm
DEF 14A
ALNY
Alnylam Pharmaceuticals Inc
Definitive proxy
1 Apr 24
4:31pm
8-K
ALNY
Alnylam Pharmaceuticals Inc
4 Mar 24
Departure of Directors or Certain Officers
4:33pm
10-K
2023 FY
ALNY
Alnylam Pharmaceuticals Inc
Annual report
15 Feb 24
4:23pm
8-K
wwdg96kvpxze
15 Feb 24
Results of Operations and Financial Condition
8:10am
8-K
rifz2duv37gqrx
19 Jan 24
Departure of Directors or Certain Officers
4:31pm
8-K
nls jbsonj99
8 Jan 24
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
7:00am
8-K
bknhtsc zb5g
2 Nov 23
Results of Operations and Financial Condition
8:10am
8-K
1rzl00xb vg
10 Oct 23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
7:30am
8-K
qdl48 0pi7lw
28 Sep 23
Departure of Directors or Certain Officers
5:00pm
8-K
azggt898ppy9eewtv8
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
9nhk152lw0vzrwx6m27
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
hu1 vx4gdszidn7d
30 Jun 23
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
9:03am
8-K
t69o5yd1ei8ttqvnarit
23 May 23
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
py0 vrtneqheumpp7aiv
4 May 23
Results of Operations and Financial Condition
8:10am
ARS
cif 5jzz7
3 Apr 23
Annual report to shareholders
4:38pm